Author + information
- John J.V. McMurray, MD, FACC⁎ (, )
- Robert M. Califf, MD, FACC and
- Marc A. Pfeffer, MD, PhD, FACC
- ↵⁎Western Infirmary, Cardiology, Dumbarton Road, Glasgow G11 6NT, Scotland, United Kingdom
Unfortunately, Drs. Bangalore and Messerli did not cite our concluding sentence about myocardial infarction in full, omitting the final statement that our observation was “a possibilitythat needs to be prospectively tested” (1). A p value of 0.187 (for the comparison of combination treatment with captopril and valsartan versus captopril monotherapy) might, with the appropriate caution we applied in the Abstract Conclusions and elsewhere, reasonably be described as a trend. In addition, in supportive analyses using other classifications of events (e.g., investigator reported versusadjudicated) and other statistical techniques, the p value for combination versus monotherapy was nominally statistically significant.
Overall, strokes were numerically fewer in the combination treatment group than in the captopril-only group, with a p value of 0.079, which, according to Drs. Bangalore and Messerli’s own criteria, might be described as a trend. It is not clear why one would try to segment the Kaplan-Meier curves into 6-month time periods.
We clearly stated that our observations had been made in a post hocanalysis, were not conclusive, and required prospective testing. Fortunately, such a trial has been conducted and will be reported in the near future (2).
- American College of Cardiology Foundation
- McMurray J.,
- Solomon S.,
- Pieper K.,
- et al.
- Teo K.,
- Yusuf S.,
- Sleight P.,
- et al.,
- ONTARGET/TRANSCEND investigators